Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment | New England Journal
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has become a global public
health crisis, for which antiviral treatments are considered mainstream therapeutic …

Nirmatrelvir/ritonavir (Paxlovid) consists of a peptidomimetic inhibitor (nirmatrelvir) of the
SARS-CoV-2 main protease and a pharmacokinetic enhancer (ritonavir). It is approved for …

This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …

Deuremidevir hydrobromide tablets and simnotrelvir tablets/ritonavir tablets (co-packaged)
were approved by the Chinese National Medical Products Administration for the treatment of …

As the SARS-CoV-2 pandemic remains uncontrolled owing to the continuous emergence of
variants of concern, there is an immediate need to implement the most effective antiviral …

The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …

Abstract Nirmatrelvir (PF-07321332; NMV) the antiviral component of PAXLOVID™ is a
potent and selective inhibitor of the SARS-CoV-2 main protease (M pro), which plays a …

The genus Betacoronavirus includes severe acute respiratory syndrome coronavirus (SARS-
CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Historically, these …